Aclarion, Inc., a commercial-stage healthcare technology company, announced the issuance of U.S. Patent #12,601,803, titled “System for Machine Learning-Based Model Training and Prediction for Evaluation of Pain.” The patent covers the company’s machine learning–based platform for analyzing magnetic resonance spectroscopy (MRS) data, which is used in its cloud-based Nociscan platform to help physicians distinguish between painful and non-painful discs in the spine.
The newly issued patent protects Aclarion’s use of artificial intelligence in future versions of the platform, aiming to further automate biomarker identification, accelerate report generation, and reduce manual quality reviews. This advancement is expected to enable the company to scale its operations efficiently while enhancing already strong gross margins.
“This patent strengthens the foundation of our platform by protecting how we leverage AI to transform complex spectroscopy data into meaningful, actionable information that physicians can integrate into everyday practice,” said Brent Ness, Chief Executive Officer of Aclarion. “By combining proprietary signal processing with machine learning, we are building a scalable and defensible approach to evaluating pain that has the potential to redefine how spine conditions are assessed while enabling highly efficient scaling and strong gross margin expansion.”
The patent specifically covers machine learning models that extract quantitative biomarkers from MRS spectral data to generate standardized classifications associated with pain-related conditions. It also includes AI-based automated data quality controls that detect and exclude low-quality acquisition signals, such as excessive lipids, low signal-to-noise ratio, or spectral artifacts. This capability is designed to ensure consistent, reproducible outputs across different imaging systems and sites, representing a key step toward broader clinical adoption.
With this addition, Aclarion’s intellectual property portfolio now includes 64 issued and pending patents worldwide. The company’s strategy focuses on building a differentiated, software-driven platform in the large and underserved chronic low back pain market. Chronic low back pain affects approximately 266 million people globally. Clinical data has demonstrated up to a 97% surgical success rate when all Nociscan-positive discs are treated, according to the company.
The full patent can be read here. More information about Aclarion and Nociscan is available on the company’s website at www.aclarion.com.
